Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03014830 · ClinicalTrials.gov registry record · Phase 1
Alirocumab and Reverse Cholesterol Transport
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03014830 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 28 participants.
The verdict
NCT03014830, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
Alirocumab is an injectable treatment for elevated blood cholesterol. The hypothesis of this study is that it also increases cholesterol excretion from the body into the stool, a process sometimes called reverse cholesterol transport. A cholesterol metabolic study will be done before and after 6 weeks of alirocumab treatment. If alirocumab increases reverse cholesterol transport, it is possible that this action provides additional protection from cardiovascular disease.
Interventions
- DRUG Placebos
- DRUG Alirocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2018-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03014830
The ClinicalTrials.gov registry entry for NCT03014830 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03014830 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03014830 about?
NCT03014830 is a clinical study titled "Alirocumab and Reverse Cholesterol Transport". Alirocumab is an injectable treatment for elevated blood cholesterol. The hypothesis of this study is that it also increases cholesterol excretion from the body into the stool, a process sometimes called reverse cholesterol transport. A cholesterol metabolic study will be done before and after 6 wee...
What is the current status of trial NCT03014830?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2017-06-01. Estimated completion is 2018-07-30.
What interventions are being tested in trial NCT03014830?
The interventions under investigation include: Placebos (DRUG), Alirocumab (DRUG).
Who is sponsoring clinical trial NCT03014830?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.